- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01911000
Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis
Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis: Prospective Phase II Trial
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
1.1 Hepatocellular carcinoma (HCC) and standard treatment HCC is the third most common cause of cancer death globally. It is also the second cause of cancer mortality in Korea, despite the incidence of HCC was fifth. The most important cause of this discrepancy is connected with the fact that the significant portion of the HCC is detected as unresectable status. At the point of HCC diagnosis, only 30% of the patients could receive standard curative treatment, like resection, liver transplantation, and radiofrequency ablation (RFA), TACE has been shown in randomized trials to improve survival compared with symptomatic therapy alone, in the patients without macrovascular involvement, extrahepatic disease and tumor related symptoms. However, in the recent review of TACE, TACE might be contraindicate or not recommended in the patients who showed vascular tumor invasion, more than 10 cm size, poor portal blood flow and/or repeated poor response.
1.2 HCC with PVTT The presence of PVTT in patients with HCC is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months. Recently, Sorafenib, which is one of the target agents, showed survival advantage on unresectable HCC patients in two randomized study. In those study, sorafenib improved approximately three month overall survival increment, however, the median survival duration was only 10.7 months in experiment group (received sorafenib), and even 6.5 months in Asian-Pacific trial. Additionally, the possibility that sorafenib effect could be reduced in the patients had hepatitis B virus (HBV) was suggested in the subgroup analysis.
1.3 Radiation therapy (RT) for the HCC The use of RT in HCC is increased with the radiation technological advances. In the unresectable patients, RT showed 50 to 60% response rate with the dose response relationship. Especially, in the HCC patients who combined with PVTT, RT showed 50% of local control and about 10 months survival duration. Despite the standard treatment of the HCC combined with PVTT is sorafenib, but Korean Liver Cancer Study Group (KLCSG) recommend RT as an option in those patients.
Investigators previously reported the retrospective study that the scheduled interval TACE followed by RT for HCC combined with PVTT and 60% of the patients showed objective response without significant elevation of complication.
1.4 Hyperthermia It is reported that hyperthermia is effective in S phase, Low partial oxygen pressure (pO2), acidic condition, and low perfusion site which are known as radio-resistant. Because of these characteristics, it considered as the most valuable radiosensitizer in cancer treatment, theoretically. Furthermore ,mild hyperthermia (41 to 41.5 ºC) can promote tumor reoxygenation.
1.5 Purpose of the study Based on those studies, we start this prospective study to evaluate the objective response and adverse event in the combination treatment of RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT.
2. Hypothesis and sample size Several prospective trials showed 50% to 60% of objective response rate when conventional RT was administered for HCC with PVTT, thus we determined the objective response rate of conventional RT as 60%. We expect additional 20% increase of the local progression free rate than conventional RT when treated with combined RT and hyperthermia for HCC with PVTT.
To determine sample size, we designed to have 80% power to detect an absolute difference of 20% points in objective response rate between combined RT and hyperthermia and conventional RT, with a two-sided alpha level of 0.05. A total of 87 patients are required for this study considering a drop-out rate of 10%.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Seoul, Korea, Republikken, 135-710
- Samsung Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients must have a diagnosis of HCC by at least one criterion listed below (korean liver cancer study group (KLCSG) guideline 2009) 1.1 Pathologically (histologically or cytologically) proven diagnosis of HCC 1.2 Liver nodule in high risk group 1.2.1 If alpha fetoprotein (AFP) ≥200 ng/mL , ≥ 1 typical HCC enhancing pattern on dynamic contrast enhanced CT or MRI 1.2.2 If AFP<200 ng/mL, ≥2 typical HCC enhancing pattern on dynamic contrast enhanced CT, MRI, and angiography 1.3 ≥ 2 cm nodule in liver cirrhosis (LC), ≥ 1 typical HCC enhancing pattern on dynamic contrast enhanced CT or MRI
- Patients must have a diagnosis of PVTT 2.1 Early arterial enhancement and delayed washout on multiphasic CT or MRI
- Eastern cooperative oncology group performance status 0 1 2
- Age ≥ 20
- Unsuitable for resection or transplant or RFA
- Unsuitable for or refractory to TACE or drug eluting beads (DEB)
- Agreement of study-specific informed consent
- Assessment by radiation oncologist and medical oncologist or hepatologist within 28 days prior to study entry?
- Child-Pugh score A-B within 7 days prior to study entry
- Normal liver (Liver minus gross tumor volume) ≥ 700 cc
Blood work requirements
- Absolute neutrophil count (ANC) ≥ 1,500 /mm3, Platelet ≥ 70,000/mm3, Hgb ≥ 8 g/dl
- Liver function test (LFT): Total bilirubin<3.0 mg/dL, International normalized ratio(INR) < 1.7, Albumin ≥ 2.8g/dL, Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT)< 6 X normal
- Serum creatinine < 1.5 X normal, or creatinine clearance ≥ 60 mL/min
- Male, consent contraception at least 6 months
- Childbearing potential woman, consent contraception at least 6 months
- Life expectancy more than 12 weeks
- Stable breathing more than 5 minutes
Exclusion Criteria:
- Complete obstruction of main portal vein
- Pregnant and/or breastfeeding woman
- Previous upper abdominal RT history
- Uncontrolled active co-morbidity
- Another primary cancer history within 2 years
- Uncontrolled ascites or hepatic encephalopathy
- Connective tissue disease which known as radiation hypersensitivity
- Uncontrolled moderate to severe gastroduodenal ulcer or esophagogastric varices
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: RTHT
RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Hyperthermia effect and averse event in RT for HCC with PVTT
Tidsramme: Radiologic response and adverse event will be evaluated at 3 month after treatment.
|
Modified response evaluation criteria in solid tumor(mRECIST) will be used.
Objective response was defined as complete and partial response.
The common terminology criteria for adverse events (CTCAE version 4.0) will be used to evaluate the adverse events.
|
Radiologic response and adverse event will be evaluated at 3 month after treatment.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Hyperthermia effect on local progression free survival rate
Tidsramme: The liver CT or MRI will be examined at 3 month after treatment and used to determine the response and presence of progression.
|
The liver CT or MRI will be examined at 1, 3 month after treatment, after that 3 month follow-up with above images and used to determine the presence of local progression.
Progression free survival will be measured from the date of RT start to the date of local progression recognition or last follow up visit.
|
The liver CT or MRI will be examined at 3 month after treatment and used to determine the response and presence of progression.
|
To measure the time to local tumor progression
Tidsramme: The liver CT or MRI will be examined at 3 month after treatment.
|
The liver CT or MRI will be examined at 1, 3 month after treatment, after that 3 month follow-up with above images and used to determine the presence of local progression.
Time to local tumor progression will be measured from the date of RT start to the date of local progression recognition.
|
The liver CT or MRI will be examined at 3 month after treatment.
|
To measure the overall survival
Tidsramme: First follow up will be at 1 month after treatment.
|
he follow up will be at 1, 3 month after treatment, after that every 3 month.
Overall survival will be measured from the date of RT start to the date of death or last follow up visit.
|
First follow up will be at 1 month after treatment.
|
Quality of life (QoL) change before and after treatment
Tidsramme: QoL will be assessed before, 1, 3, 6 months after RT and compared each other.
|
QoL will be assessed before, 1, 3, 6 months after RT and compared each other.
|
|
To validate of the prognostic index of portal vein tumor thrombosis in HCC (PITH) staging system
Tidsramme: The liver CT or MRI will be examined at 3 month after treatment
|
Overall survival outcome will be used to validate PITH staging system.
|
The liver CT or MRI will be examined at 3 month after treatment
|
To evaluate RT response prediction probability by diffusion-weighted (DW) MRI
Tidsramme: DW MRI will be evaluated at 1 month after treatment.
|
DW MRI will be evaluated at 1 month after treatment.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Hee Chul Park, M.D., Ph.D., Samsung Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Hjerte-kar-sygdomme
- Karsygdomme
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Adenocarcinom
- Neoplasmer, kirtel og epitel
- Sår og skader
- Neoplasmer i fordøjelsessystemet
- Leversygdomme
- Embolisme og trombose
- Neoplasmer i leveren
- Ændringer i kropstemperaturen
- Varmestressforstyrrelser
- Karcinom
- Carcinom, hepatocellulært
- Trombose
- Hypertermi
Andre undersøgelses-id-numre
- 2013-06-013-003
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Carcinoma. Hepatocellular
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk Ureter Urothelial Carcinoma | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Metastatisk nyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Metastatisk Urothelial Carcinom | Lokalt avanceret blæreurothelial karcinom | Lokalt avanceret nyrebækken Urothelial Carcinoma | Lokalt... og andre forholdForenede Stater
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.Trukket tilbageMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Uoperabelt nyrebækken Urothelial Carcinom | Uoperabelt Ureter Urothelial CarcinomaForenede Stater
-
All India Institute of Medical Sciences, New DelhiUkendtHOVED- OG NAKKEKRÆFT | CARCINOMA OROPHARYNX | CARCINOMA PYRIFORM SINUS | CARCINOMA LARYNXIndien
-
Barbara Ann Karmanos Cancer InstituteBristol-Myers SquibbAfsluttetStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Stadie II Blære Urothelial Carcinoma AJCC v6 og v7Forenede Stater
-
National Cancer Institute (NCI)RekrutteringNyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
National Cancer Institute (NCI)AfsluttetNivolumab til behandling af patienter med tilbagevendende og/eller metastatisk nasopharyngeal cancerTilbagevendende nasopharynx carcinom | Stadie III Nasopharyngeal Carcinoma AJCC v7 | Stadie IV Nasopharyngeal Carcinoma AJCC v7 | Stadie IVA Nasopharyngeal Carcinoma AJCC v7 | Stadie IVB Nasopharyngeal Carcinoma AJCC v7 | Stadie IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal ikke-eratiniserende...Forenede Stater, Singapore, Kina
-
National Cancer Institute (NCI)RekrutteringStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Stadie II Blære Urothelial Carcinoma AJCC v6 og v7 | Muskelinvasiv blære Urothelial CarcinomForenede Stater
-
University of California, San FranciscoAmgenTrukket tilbageStadie 0a Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie 0 er blæreurothelial karcinom AJCC v6 og v7 | Stadie I Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie 0 Blære Urothelial Carcinoma AJCC v6 og v7Forenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Fase III Ureterkræft AJCC v7 | Lokalt avanceret blæreurothelial karcinom | Lokalt avanceret Ureter Urothelial Carcinoma | Lokalt avanceret Urothelial Carcinom | Lokaliseret nyrebækken og Ureter Urothelial Carcinoma | Stadie II Blære Urothelial... og andre forholdForenede Stater, Guam